← All Prothena CORP Public LTD CO filings

Prothena CORP Public LTD CO 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
PRTA
Prothena CORP Public LTD CO
10-K: Prothena 2025 Annual Report: Pipeline Progress Amid Restructuring
Prothena's 2025 annual report highlights advancements in its partnered neurodegenerative and amyloidosis programs, alongside a significant workforce reduction and a net loss of $244.1 million.
NASDAQ
PRTA
Prothena CORP Public LTD CO
10-K: Prothena Corporation Reports 2024 Financial Results and Provides Business Update
Prothena Corporation's 2024 10-K filing highlights the company's focus on developing therapies for neurodegenerative and rare peripheral amyloid diseases, with key clinical trial milestones expected in 2025.
NASDAQ
PRTA
Prothena CORP Public LTD CO
10-K: Prothena Outlines Share Structure and Governance in SEC Filing
Prothena Corporation plc details its share capital, shareholder rights, and corporate governance practices in its latest 10-K filing.